Elucid Raises $55M for Heart Imaging
Elucid raised $55M to expand AI-powered cardiovascular imaging software and clinical studies.
AI in healthcare is moving deeper into regulated clinical workflows. Elucid’s round is a useful signal because it targets cardiovascular imaging, where better analysis can affect diagnosis, treatment planning and patient outcomes.
What happened
Elucid closed an oversubscribed $55M Series D to expand its AI-powered cardiovascular imaging software. The funding is expected to support commercial expansion, AI research and development, clinical studies and its FFR-CT product, which is under FDA review.
The company focuses on software that helps clinicians assess cardiovascular disease from imaging data. That makes it part of a more mature healthtech category: AI tools that support existing clinical decisions rather than trying to replace clinicians outright.
Why it matters
Cardiovascular disease is high-volume, high-cost and clinically complex. Imaging interpretation can be slow and variable, especially when clinicians need to understand plaque, vessel structure and disease progression.
AI tools that improve consistency or speed in this workflow can become valuable infrastructure for hospitals, imaging centres and specialist care teams.
The bigger picture
The healthtech AI market is splitting between lightweight wellness products and more serious regulated software. Elucid sits in the second camp. The round shows that investors are still willing to back medical AI when there is a clear clinical use case, regulatory path and commercial market.